M28 Capital Management LP
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 13, 2025), M28 Capital Management LP reported 11 stock positions worth $101.9 million. Its top holding was Wave Life Sciences (WVE) at 68.8% of the portfolio, followed by TG Therapeutics (TGTX, 4.8%) and Rocket Pharmaceuticals (RCKT, 4.8%). Compared with Q3 2024, it added to 1 and reduced 1. The biggest buy was Curis (CRIS, shares +23%) and the biggest sale Wave Life Sciences (WVE, shares −8%).
- Most Recent 13F
- Q2 2026
- Location
- STAMFORD, CT
- CIK
- 0001807489
- Portfolio Value
- $101.9M (Q4 2024)
- SEC Filing
- 0000902664-25-000931 ↗ filed Feb 13, 2025
Holdings Value
Holdings 11 stocks · $101.9M
| WVE Wave Life Sciences Ltd. | 68.79% | 5,664,548 | $70.1M | Reduce -8.1% |
| TGTX TG Therapeutics Inc. | 4.78% | 161,600 | $4.9M | No change |
| RCKT Rocket Pharmaceuticals Inc. | 4.76% | 385,680 | $4.8M | No change |
| IVVD Invivyd Inc. | 4.02% | 9,248,250 | $4.1M | No change |
| SWTX Springworks Therapeutics Inc. | 3.92% | 110,400 | $4.0M | No change |
| GUTS Fractyl Health Inc. | 3.75% | 1,856,117 | $3.8M | No change |
| BBIO Bridgebio Pharma Inc. | 3.27% | 121,200 | $3.3M | No change |
| PRQR Proqr Therapeutics NV | 2.65% | 1,019,498 | $2.7M | No change |
| CRIS Curis Inc. | 1.57% | 521,059 | $1.6M | Add +23.5% |
| SLN Silence Therapeutics PLC-ADR | 1.25% | 185,100 | $1.3M | No change |
| ARWR Arrowhead Pharmaceuticals Inc. | 1.24% | 67,400 | $1.3M | No change |
Portfolio Sells Q3 2024 → Q4 2024
| WVE Wave Life Sciences Ltd. | Reduce -8.1% | 68.79% | +13.25 |
Portfolio Buys Q3 2024 → Q4 2024
| CRIS Curis Inc. | Add +23.5% | 1.57% | −0.93 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 9 | $47.2M | WVE, IVVD, TGTX, ARWR, GUTS |
| Q1 2026 | 9 | $53.8M | WVE, IVVD, TGTX, ARWR, PRQR |
| Q4 2025 | 9 | $137.6M | WVE, IVVD, TGTX, ARWR, GUTS |
| Q3 2025 | 9 | $68.0M | WVE, IVVD, TGTX, GUTS, ARWR |
| Q2 2025 | 9 | $58.6M | WVE, IVVD, TGTX, GUTS, PRQR |
| Q1 2025 | 11 | $73.0M | WVE, TGTX, IVVD, BBIO, RCKT |
| Q4 2024 | 11 | $101.9M | WVE, TGTX, RCKT, IVVD, SWTX |
| Q3 2024 | 11 | $91.0M | WVE, IVVD, RCKT, GUTS, TGTX |
| Q2 2024 | 11 | $77.1M | WVE, IVVD, RCKT, GUTS, SWTX |
| Q1 2024 | 11 | $135.3M | WVE, IVVD, GUTS, RCKT, SLN |